Incruse Ellipta

Umeclidinium bromide, the active ingredient in Incruse Ellipta, is a Long‑acting muscarinic antagonist (LAMA) presented as a 62.5 µg per inhalation dry powder inhaler for inhalation use. It treats chronic obstructive pulmonary disease (COPD) as a maintenance therapy in adult patients.

GNH USA supplies Incruse Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Incruse Ellipta (umeclidinium bromide) is a long‑acting muscarinic antagonist used in the management of chronic obstructive pulmonary disease.

- Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation to improve airflow and reduce exacerbations.

Common Side Effects: - Cough: mild to moderate irritation of the throat. - Dry mouth: reduced salivary flow. - Throat irritation: discomfort after inhalation. - Headache: transient mild headache. - Nasopharyngitis: upper respiratory tract infection symptoms. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Allergic reactions: rash, pruritus, or angioedema. - Urinary retention: difficulty emptying the bladder. - Narrow‑angle glaucoma: increased intra‑ocular pressure. - Tachycardia: elevated heart rate. - Severe hypersensitivity: anaphylactic response.

Before initiating therapy, evaluate the patient’s COPD diagnosis and baseline lung function. Monitor for anticholinergic adverse events, especially in patients with pre‑existing urinary or ocular conditions. Avoid use in individuals with narrow‑angle glaucoma or uncontrolled urinary retention. Review concomitant anticholinergic medications to minimise cumulative effects. Educate patients on correct inhaler technique to ensure optimal drug delivery.

Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Major Interactions (Avoid): - Concurrent long‑acting anticholinergics: may increase anticholinergic burden and risk of side effects. - Strong CYP3A4 inhibitors: can raise systemic exposure of umeclidinium. - Beta‑agonists in high doses: may cause excessive bronchodilation, requiring monitoring.

Moderate Interactions (Monitor Closely):\n- Short‑acting muscarinic antagonists (e.g., ipratropium): additive anticholinergic effects. - Other anticholinergic drugs (e.g., antihistamines): monitor for dry mouth and urinary retention. - Diuretics: may exacerbate urinary retention risk.